和鉑醫藥-B：2023年年報

Futu NewsApr 25 07:05 · Announcements

Hebo Pharmaceutical-B (02142.HK) issued 98,000 shares under the share award scheme on April 18

Hebo Pharmaceutical-B (02142.HK) issued an announcement to issue 98,000 shares on April 18, 2024 in accordance with the initial public offering after-sales share incentive plan adopted and approved by the company's shareholders on November 23, 2020.

Zhitong FinanceApr 18 18:35

Featured announcements | Xiaopeng and Volkswagen reached a strategic technical cooperation; Sands China's total net revenue increased 42% year over year

Anta Sports: The retail value of Anta brand products achieved a positive year-on-year increase in the number of units in the first quarter; China Building Materials expects a 147% year-on-year increase in net loss for the first quarter.

cls.cnApr 18 08:10

Wang Jingsong, chairman of the board of directors of Harbour BioMed (02142), promised not to reduce the company's shares for at least six months

Hebo Pharmaceutical-B (02142) announced that Dr. Wang Jinsong, Executive Director, Chief Executive Officer and Chairman of the Board of Directors, has voluntarily promised...

Zhitong FinanceApr 17 16:31

Hebo Pharmaceutical-B (02142.HK) grants 8.38,000 share options and 3.105 million share awards

On April 3, 2024, Gelonghui Pharmaceutical-B (02142.HK) announced that on April 3, 2024, according to the share option plan and share award plan separately adopted by the company's shareholders on November 23, 2020, the company granted 8.310,000 share options and 3.105 million share awards to eligible participants, subject to acceptance by the grantor.

Gelonghui FinanceApr 3 19:06

HBM Holdings Returns to Profitability in 2023

HBM Holdings (HKG:2142) recorded a profit of $22.8 million in 2023, as opposed to a loss of $137.3 million in the previous year, according to a March. 28 filing with the Hong Kong bourse. Basic earnin

MT NewswiresApr 2 21:19